Search results for: 'software revenue model'

The medical marijuana market is growing in the United States despite the fact that the Food and Drug Administration (FDA) has not yet approved any medical marijuana products. These marijuana-based products have not yet passed through the rigorous tests and clinical trials required for medical drug approvals in the United States. At the Federal le...

20 Jun 2017  |  North America  |  Market Research

Transformation and Growth Opportunities in the US Next-Generation Sequencing Informatics Market

Pharmaceutical and Molecular Diagnostics Segments to Lead Revenue Growth

Infographics

×

Frost & Sullivan expects strong demand for commercial application-focused solutions to drive new investments in the development of tools and technologies, and will also result in consolidation of the US next-generation sequencing informatics market. Changing customer requirements and intense competition will drive the transformation. As companies l...

20 Mar 2019  |  North America  |  Market Research

Growth Opportunities in the North American Clinical Laboratory Services Market, Forecast to 2022

Laboratories Seek Alternate Revenue Streams to Combat Reimbursement Pressure

Infographics

×

Clinical laboratory services represent one of the highest healthcare expenditures in North America, yet the United States and Canada represent different scenarios in the way clinical services are rendered. The market for clinical lab services in Canada was an estimated $10.33 billion in 2017 whereas in the United States it was an estimated $78.33 b...

31 Oct 2017  |  Global  |  Market Research

Global Digital Pathology Market, 2017 Companies-To-Action

Collaborative Business Models Embracing Artificial Intelligence Application in Novel Disease Areas to Drive Market Growth

Infographics

×

It is estimated that more than 19,000 pathologists would be needed to serve the US healthcare needs. However, the actual number is expected to be approximately 40% lesser. Similar trends are foreseen globally driven by aging population and widening application in areas such as cancer diagnostics, drug development, clinical trials, biomarker discove...

The healthcare landscape is experiencing a profound shift as it shifts away from traditional fee-for-service models toward value-based care. This transition emphasizes collaboration among healthcare stakeholders, fostering a patient-centric approach. The focus is not merely on the quantity of services delivered but also on the quality of care, enco...

Given the ever increasing cost of care, healthcare delivery is moving towards decentralisation. Service delivery from healthcare settings such as mobile clinics, rapid retail clinics, and home settings demands the use of new-age clinical laboratory diagnostics. The effective delivery of healthcare services has created a business and technology conv...

The laboratory information management systems (LIMS) market in the United States has been a mature space for many years. The evolution of laboratory needs has spurred innovation in this industry, forcing vendors to change their approach toward consumers. Consumers have the option of choosing between thick-client (Web-enabled) solutions, thin-client...

27 Jan 2020  |  Global  |  Market Research

Growth Opportunities—Contract Manufacturing and Outsourcing Opportunities in the In-vitro Diagnostics (IVD) Industry, 2019 to 2022

Consolidation and Innovative Business Models Will Accelerate IVD Outsourcing Growth

Infographics

×

Key Issues Addressed

The increasing pressure for cost-driven development and regulatory and regional trends are inducing industry participants to adopt innovative integrated business models so as to align themselves as one-stop-shop solution providers as opposed to the traditional functional service providers, thereby, creating a mutually beneficial symbiotic relations...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...